BRAF Mutations in Colorectal Cancer

by Jason Wasserman MD PhD FRCPC
March 24, 2026

A BRAF mutation is found in approximately 8 to 12% of colorectal cancers and identifies a biologically distinct subtype of the disease with its own treatment implications. The great majority of BRAF mutations in colorectal cancer are a specific change called V600E. This mutation carries two important clinical consequences: it predicts that standard anti-EGFR targeted therapy will not work, and it is associated with a more aggressive disease course than BRAF wild-type colorectal cancer. At the same time, the identification of a BRAF V600E mutation now opens the door to specific targeted treatments that were not available even a few years ago, and the treatment landscape for BRAF-mutated colorectal cancer is advancing quickly. BRAF testing also plays a critical role in understanding why a tumour’s DNA repair system has failed — an important step in determining whether Lynch syndrome may be present.

What BRAF is and what it does

BRAF is a gene that provides instructions for making a protein — the B-Raf protein — that acts as a relay switch inside cells. It sits at the centre of a signalling pathway called the RAS-RAF-MEK-ERK pathway, which carries messages from the cell surface to the cell’s nucleus, telling the cell when to grow and divide. In a healthy cell, BRAF activates briefly in response to incoming growth signals and then switches off again. This keeps cell division under tight control.

When BRAF carries a mutation, the protein can become permanently activated — stuck in the “on” position — even without any incoming signal. The result is a constant, unchecked drive for the cancer cells to proliferate. The most common mutated form of this protein in colorectal cancer is the V600E variant, in which a single amino acid substitution confers constitutive activation.

Unlike KRAS and NRAS mutations, which are each found in roughly 40–45% and 4–5% of colorectal cancers, respectively, BRAF mutations are less common, present in approximately 8-12% of cases. BRAF and KRAS mutations very rarely occur together in the same tumour; they tend to be mutually exclusive because they affect the same pathway.

Why is the test done

To determine anti-EGFR therapy eligibility

Because BRAF sits in the same growth signalling pathway as KRAS and NRAS — just one step downstream — a BRAF V600E mutation bypasses the EGFR receptor in the same way a KRAS mutation does. Anti-EGFR drugs such as cetuximab (Erbitux) and panitumumab (Vectibix) block the EGFR receptor at the cell surface. Still, if BRAF is already permanently activated further down the pathway, that block is irrelevant. Anti-EGFR therapy is therefore not expected to be effective in BRAF V600E-mutated colorectal cancers, and current guidelines recommend against its use as a single agent in this group.

This is why complete testing for all three members of this pathway — KRAS, NRAS, and BRAF — is needed before anti-EGFR therapy can be considered. A patient whose tumour is KRAS wild-type and NRAS wild-type remains ineligible for anti-EGFR therapy if it harbours a BRAF V600E mutation.

To guide treatment selection: BRAF-targeted therapy.

A BRAF V600E mutation is now an actionable finding in colorectal cancer. Specific drugs that target the mutant BRAF protein — called BRAF inhibitors — have been approved for use in combination with other targeted agents, and response rates in BRAF-mutated colorectal cancer have improved substantially as a result. Identifying a BRAF V600E mutation is therefore essential so that eligible patients can be offered these newer treatment options.

To provide prognostic information

BRAF V600E-mutated colorectal cancer is associated with a worse prognosis than BRAF wild-type disease of the same stage. These tumours tend to arise more often in the right side of the colon (the ascending colon and cecum), more often in older women, and more often in association with a poorly differentiated or mucinous histology. They have a higher likelihood of peritoneal spread (spread to the lining of the abdominal cavity) and a more aggressive course in the metastatic setting. This makes early and accurate identification of BRAF mutation status important for setting expectations and promptly planning treatment.

To help interpret MMR/MSI results and evaluate for Lynch syndrome

BRAF V600E testing plays a specific and important role in interpreting mismatch repair (MMR) test results. When a colorectal tumour shows loss of the MLH1 protein on MMR testing — a common pattern of MMR deficiency — BRAF V600E testing is used to help determine whether that loss is due to Lynch syndrome (an inherited condition) or a sporadic, non-inherited cause. A BRAF V600E mutation found alongside MLH1 loss strongly indicates a sporadic tumour rather than Lynch syndrome, because Lynch syndrome-related cancers rarely carry a BRAF V600E mutation. This interpretation is explained in more detail in the MMR/MSI article for colorectal cancer.

How common is the BRAF V600E mutation in colorectal cancer?

BRAF V600E mutations are found in approximately 8 to 12% of all colorectal cancers. Within the subgroup of tumours that are also MMR-deficient (dMMR/MSI-H), the frequency of BRAF V600E mutation is considerably higher — around 40 to 50% — because the sporadic form of dMMR (caused by MLH1 methylation rather than Lynch syndrome) is strongly associated with BRAF V600E.

BRAF V600E-mutated colorectal cancers have a characteristic profile: they are more common in the right colon, more common in older patients (particularly older women), and more likely to be poorly differentiated or mucinous. They are less common in rectal cancers. These clinical features can raise suspicion for BRAF mutation before test results are available, but testing is required to confirm.

Non-V600E BRAF mutations also exist but are uncommon, accounting for roughly 2 to 3% of colorectal cancers. These are discussed briefly in a separate section below.

How the test is performed

BRAF testing is performed on tumour tissue from a biopsy or surgically removed specimen. The tissue used is usually the same sample already collected for diagnosis — no additional procedure is typically needed. The most common testing methods are:

PCR-based testing. Targeted PCR assays can rapidly detect the specific BRAF V600E mutation and a small number of other common BRAF mutations. These tests are fast and widely used. Some PCR kits are FDA-approved companion diagnostics specifically designed for guiding BRAF-targeted treatment decisions.
Next-generation sequencing (NGS). NGS panels test for BRAF mutations alongside KRAS, NRAS, MMR status, and many other cancer genes simultaneously. NGS can detect a broader spectrum of BRAF mutations beyond V600E and is increasingly the method of choice for comprehensive biomarker testing in colorectal cancer.

In most centres, BRAF testing is ordered alongside KRAS, NRAS, and MMR testing as part of a standard molecular panel for colorectal cancer — meaning patients typically do not have to wait for these results separately.

How results are reported

Your pathology report will describe the BRAF result in the molecular testing or biomarker section. Common ways results are reported include:

BRAF wild-type / no BRAF mutation detected. No mutation was found in the BRAF gene. This is the result in approximately 88 to 92% of colorectal cancers. A wild-type BRAF result, combined with wild-type KRAS and NRAS, means BRAF is not a barrier to anti-EGFR therapy consideration (though tumour location and other factors still apply).
BRAF V600E mutation detected. The specific V600E mutation was found. This is the clinically most important BRAF result in colorectal cancer. The report may describe it as “BRAF p.V600E,” “BRAF c.1799T>A,” or simply “BRAF V600E positive.” This result identifies the tumour as a candidate for BRAF-targeted therapy and rules out anti-EGFR monotherapy.
Non-V600E BRAF mutation detected. A BRAF mutation other than V600E was found. The specific mutation will be named. The treatment implications differ from V600E (see below).

What the result means

BRAF wild-type

A BRAF wild-type result means the BRAF gene did not show a mutation at the regions tested. This is the most common result. In the context of anti-EGFR therapy planning, a wild-type BRAF result is one of the required conditions for eligibility — combined with wild-type KRAS and NRAS — and confirms that BRAF-targeted therapy is not relevant. Your treatment planning will proceed based on the overall molecular profile, stage, and tumour location.

BRAF V600E mutation

A BRAF V600E mutation result has several important implications:

Anti-EGFR therapy (cetuximab or panitumumab) is not recommended alone. The mutation activates the same growth pathway that anti-EGFR drugs aim to interrupt, rendering standard anti-EGFR monotherapy ineffective. Anti-EGFR antibodies may be used as part of BRAF-targeted combination regimens (see below), but not as conventional anti-EGFR therapy.
BRAF-targeted combination therapy is now available. Two distinct treatment strategies have now been approved or are advancing rapidly in clinical trials (see the treatment section below).
Prognosis is generally more guarded than BRAF wild-type disease. BRAF V600E-mutated metastatic colorectal cancer has historically had a poor prognosis with standard chemotherapy. The development of BRAF-targeted combinations has substantially changed this, but BRAF V600E remains a marker of higher-risk disease, and prompt discussion of treatment options is important.
MMR/MSI testing results should be reviewed together. Approximately 20-30% of BRAF V600E-mutated colorectal cancers are also dMMR/MSI-H, and those tumours may be eligible for immunotherapy in addition to BRAF-targeted therapy. The majority (roughly 70 to 80%) are MMR-proficient (pMMR/MSS), and for that group, standard immunotherapy is generally not effective — BRAF-targeted therapy is the primary targeted option.

Non-V600E BRAF mutations

Non-V600E BRAF mutations (sometimes called Class 2 or Class 3 BRAF mutations) are uncommon in colorectal cancer but carry distinct features worth understanding. Unlike V600E mutations, which strongly activate the BRAF protein in isolation, non-V600E mutations often activate it through different mechanisms or at lower levels. Critically, some non-V600E BRAF mutations — particularly Class 3 mutations such as D594N/G — can co-occur with KRAS or NRAS mutations in the same tumour, which is essentially never seen with V600E.

From a treatment standpoint, non-V600E BRAF mutations also predict resistance to anti-EGFR therapy, so this finding still rules out cetuximab or panitumumab as a standard option. However, the BRAF inhibitor combinations developed for V600E (such as encorafenib) are not expected to be effective for non-V600E mutations, because those drugs are designed specifically to target the V600E form of the protein. If you have a non-V600E BRAF mutation, your oncologist will discuss what it means for your specific treatment plan, and clinical trial participation may be particularly relevant.

Treatment implications of BRAF V600E in colorectal cancer

The treatment of BRAF V600E-mutated metastatic colorectal cancer has been transformed over the past several years by the development of combination regimens that directly target the mutant BRAF protein. There are now approved options for both first-line (newly diagnosed metastatic) and previously treated disease.

Why BRAF inhibitors must be combined with anti-EGFR therapy in colorectal cancer

An important feature of BRAF V600E colorectal cancer — which distinguishes it from BRAF-mutated melanoma — is that blocking BRAF alone is not sufficient. When BRAF is inhibited, colorectal cancer cells rapidly compensate by activating a feedback loop through the EGFR receptor, effectively reactivating the same pathway through a different route. This is why BRAF inhibitors used as single agents produce very limited responses in colorectal cancer, even though they work well in melanoma. The solution is to block both BRAF and EGFR simultaneously: the BRAF inhibitor targets the mutant protein directly, while an anti-EGFR antibody blocks the feedback escape route. This combination approach is the foundation of all approved BRAF-targeted regimens in colorectal cancer.

Previously treated metastatic disease: encorafenib plus cetuximab (BEACON)

Encorafenib (Braftovi) is a BRAF inhibitor — a drug that directly blocks the mutant BRAF V600E protein. The combination of encorafenib plus the anti-EGFR antibody cetuximab (Erbitux) is FDA-approved for patients with BRAF V600E-mutated metastatic colorectal cancer who have received one or two prior lines of chemotherapy. This approval was based on the phase III BEACON CRC trial, in which encorafenib plus cetuximab produced an overall response rate of approximately 20% and a median overall survival of 8.4 months — roughly double the 5.4-month survival seen with standard chemotherapy in the same setting. While response rates remain modest, the improvement in survival over the prior standard of care was clinically meaningful for a population with very limited options.

First-line metastatic disease: encorafenib plus cetuximab plus chemotherapy (BREAKWATER)

In December 2024, the FDA granted accelerated approval to encorafenib in combination with cetuximab and the chemotherapy regimen mFOLFOX6 (oxaliplatin, leucovorin, and fluorouracil) for patients with previously untreated BRAF V600E-mutated metastatic colorectal cancer. This approval was based on the phase III BREAKWATER trial, in which the triple combination produced an overall response rate of approximately 61%, compared to 40% with standard chemotherapy — a substantial improvement. The addition of BRAF-targeted therapy to front-line chemotherapy, therefore, represents a significant step forward for newly diagnosed metastatic BRAF V600E colorectal cancer.

The BREAKWATER approval means that patients with newly diagnosed BRAF V600E-mutated metastatic colorectal cancer now have the option of starting a BRAF-targeted regimen from the outset, rather than waiting until after standard chemotherapy. Whether this approach is right for a given patient depends on individual factors, rs including performance status, comorbidities, and the specific goals of treatment, and your oncologist will help guide that decision.

BRAF V600E with dMMR/MSI-H: a double actionable finding

Approximately 20 to 30% of BRAF V600E-mutated colorectal cancers are also dMMR/MSI-H. In these patients, both immunotherapy and BRAF-targeted therapy are potentially relevant. Pembrolizumab (Keytruda) — approved as a first-line treatment for metastatic dMMR/MSI-H colorectal cancer — may be considered alongside or instead of BRAF-targeted combinations, and clinical trials are exploring these combinations further. If your tumour is both BRAF V600E-mutated and dMMR/MSI-H, your oncologist will discuss the most appropriate sequencing or combination of these approaches for your situation. The MMR/MSI article details the immunotherapy implications of dMMR status.

Chemotherapy backbones for BRAF V600E colorectal cancer

Standard chemotherapy regimens — including FOLFOX (oxaliplatin, leucovorin, and fluorouracil), CAPOX (capecitabine and oxaliplatin), FOLFIRI (irinotecan, leucovorin, and fluorouracil), and FOLFOXIRI (a combination of all three chemotherapy drugs) — remain part of the treatment landscape for BRAF V600E-mutated colorectal cancer, either as components of BRAF-targeted combinations (as in BREAKWATER) or for patients who are not candidates for targeted therapy. VEGF inhibitors such as bevacizumab may also be added. Your oncologist will determine which regimen is most appropriate based on your overall health, prior treatments, and current goals of care.

Does a BRAF mutation have hereditary implications?

In colorectal cancer, BRAF V600E mutations are somatic — they arise within the tumour cells during a person’s lifetime and are not inherited. A BRAF mutation in your tumour does not mean your children or siblings have an elevated cancer risk from this mutation, and it does not require genetic counselling or family testing on its own.

However, because BRAF V600E testing is used to help distinguish sporadic dMMR colorectal cancer from Lynch syndrome, the broader hereditary picture should still be considered as part of your MMR/MSI evaluation. If your MMR testing showed loss of MLH1 and PMS2 and a BRAF V600E mutation was found, this pattern strongly points toward a sporadic (non-inherited) tumour rather than Lynch syndrome. Conversely, if BRAF V600E is absent in a dMMR tumour with MLH1 loss, Lynch syndrome testing is typically pursued. Your care team will guide you through this process.

What happens next

If your BRAF result has recently come back, the next steps depend on your overall situation:

If your result is BRAF wild-type, BRAF is not a treatment target and does not limit your options. Your oncologist will proceed with an anti-EGFR eligibility assessment based on your KRAS and NRAS results, tumour location, and stage.
If your result is BRAF V600E in the metastatic setting, your oncologist will discuss BRAF-targeted therapy — specifically encorafenib-based combinations — depending on whether you are newly diagnosed or have received prior treatment. The dMMR/MSI-H status of your tumour will also be reviewed, as it influences whether immunotherapy should also be considered.
If your result is BRAF V600E in early-stage (non-metastatic) disease, BRAF-targeted therapy is not currently approved in this setting, and standard surgery followed by adjuvant chemotherapy remains the primary treatment approach. Your oncologist may discuss relevant clinical trials. BRAF mutation status in early-stage disease remains important for prognosis and MMR interpretation.
If your result shows a non-V600E BRAF mutation, your oncologist will explain what this specific mutation means for your treatment plan. Anti-EGFR therapy is generally not appropriate, and participation in clinical trials may be particularly valuable.

It is worth knowing that even with recent treatment advances, BRAF V600E-mutated metastatic colorectal cancer remains a challenging diagnosis that benefits from early involvement of a specialist with experience in molecularly targeted therapies. If you are not already being treated at a centre with expertise in this area, asking about a referral or second opinion is entirely reasonable.

Questions to ask your doctor

Was my colorectal cancer tested for BRAF mutations, and what was the result?
If I have a BRAF V600E mutation, does that rule out anti-EGFR therapy with cetuximab or panitumumab?
Am I a candidate for encorafenib-based targeted therapy? If yes, which regimen — and at what point in my treatment would it be used?
Is my tumour also dMMR/MSI-H? If so, does that change the treatment approach?
How does my BRAF result interact with my KRAS and NRAS results in terms of overall treatment options?
Was BRAF testing used to help interpret my MMR result and evaluate for Lynch syndrome?
Are there clinical trials available for BRAF V600E-mutated colorectal cancer that I should know about?
Does my BRAF mutation have any implications for my family members?